The expression of GRP78 was evaluated in GBM treated with the UPR inducer TAK-243, a ubiquitin-activating enzyme 1 (UBA1) inhibitor, to inhibit tumor cell viability and, interestingly, the expression of GRP78 was related to the stem-like phenotype and increased sensitivity of these cells to the treatment (Liu et al., 2021). This evidence concerns the gene HSPA5 and glioblastoma.